NHSA Releases 2026 NRDL Update Adding 107 Drugs Including Million‑Yuan CAR‑T Therapies – Ninth List Adjustment Since the Agency’s Establishment
China's National Healthcare Security Administration (NHSA) released the National Drug List for Basic Medical Insurance, Maternity Insurance, and Work‑Related Injury Insurance (NRDL) and the Commercial Health Insurance Innovative Drug List…
JW Therapeutics Transfers Greater China and ASEAN Rights in Solid Tumor Cell Therapy Programs to Eureka – Deal Includes GPC3 and AFP‑Targeted TCR‑T Candidates
JW Therapeutics (HKG: 2126) announced that it has entered into a license and transfer agreement with Eureka Therapeutics and its affiliates covering Greater China and ASEAN regional rights to certain solid tumor cell therapy projects previously acquired by the company,…
Where biopharma's biggest deals take shape!
Hansoh Pharma Licenses AilsynBio’s AI Platform to Discover Novel Oral Cyclic Peptide Drug Candidates
Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) (HKG: 3692) announced that it has entered into a collaboration development agreement with AilsynBio, a next‑generation AI‑native biotechnology company headquartered in Hong Kong,…
NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
The Comprehensive Department of China's National Medical Products Administration (NMPA) has released the Measures for the Implementation of Drug Market Exclusivity (Draft for Comment), proposing a unified exclusivity regime that…
